Back to Search Start Over

Impact of U2AF1 mutations on circular RNA expression in myelodysplastic neoplasms.

Authors :
Wedge E
Ahmadov U
Hansen TB
Gao Z
Tulstrup M
Côme C
Nonavinkere Srivatsan S
Ahmed T
Jespersen JS
Schlotmann BC
Schöllkopf C
Raaschou-Jensen K
Ødum N
Kjems J
Bak RO
Walter MJ
Grønbæk K
Kristensen LS
Source :
Leukemia [Leukemia] 2023 May; Vol. 37 (5), pp. 1113-1125. Date of Electronic Publication: 2023 Mar 15.
Publication Year :
2023

Abstract

Mutations in U2AF1 are relatively common in myelodysplastic neoplasms (MDS) and are associated with an inferior prognosis, but the molecular mechanisms underlying this are not fully elucidated. Circular RNAs (circRNAs) have been implicated in cancer, but it is unknown how mutations in splicing factors may impact on circRNA biogenesis. Here, we used RNA-sequencing to investigate the effects of U2AF1 mutations on circRNA expression in K562 cells with a doxycycline-inducible U2AF1 <superscript>S34</superscript> mutation, in a mouse model with a doxycycline-inducible U2AF1 <superscript>S34</superscript> mutation, and in FACS-sorted CD34+ bone marrow cells from MDS patients with either U2AF1 <superscript>S34</superscript> or U2AF1 <superscript>Q157</superscript> mutations. In all contexts, we found an increase in global circRNA levels in the U2AF1-mutated setting, which was independent of expression changes in the cognate linear host genes. In patients, the U2AF1 <superscript>S34</superscript> and U2AF1 <superscript>Q157</superscript> mutations were both associated with an overall increased expression of circRNAs. circRNAs generated by a non-Alu-mediated mechanism generally showed the largest increase in expression levels. Several well-described cancer-associated circRNAs, including circZNF609 and circCSNK1G3, were upregulated in MDS patients with U2AF1 mutations compared to U2AF1-wildtype MDS controls. In conclusion, high circRNA expression is observed in association with U2AF1 mutations in three biological systems, presenting an interesting possibility for biomarker and therapeutic investigation.<br /> (© 2023. The Author(s), under exclusive licence to Springer Nature Limited.)

Details

Language :
English
ISSN :
1476-5551
Volume :
37
Issue :
5
Database :
MEDLINE
Journal :
Leukemia
Publication Type :
Academic Journal
Accession number :
36922625
Full Text :
https://doi.org/10.1038/s41375-023-01866-4